Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

The Franklin County Board of Commissioners has passed a resolution urging the Benton Franklin Health District (BFHD) to cease ...

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

Ixinity (trenonacog alfa) can effectively prevent and controlled bleeds in young children with severe or moderately severe ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...